Recent Updates
Recently added Catalysts
NCNA Positive Sentiment

NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update

Thursday, August 13, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: NuCana plc reported its second quarter 2026 financial results, highlighting that the final data from the Phase 2 expansion study of NUC-7738 is on schedule for release in 2026. The company also announced plans to advance additional indications and combination strategies for NUC-7738. Furthermore, NuCana's cash runway is projected to last until 2029.

Market Sentiment Analysis

POSITIVE FACTORS

  • Final data from Phase 2 study is on track for 2026.
  • Cash runway expected to extend into 2029.
  • Advancing additional indications and combination strategies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+151%
120-day peak, hindsight
Typical move
48.1%
average across 2 past catalysts
Lead asset
NUC-3373 + leucovorin
Phase 1 · Colorectal Cancer

Full Press Release Details

Final Data from Phase 2 Expansion Study of NUC-7738 Remains on Track for 2026 Advancing Additional Indications and Combination Strategies for NUC-7738 Cash Runway Expected to Extend into 2029 EDINBURGH, United Kingdom, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the

Frequently Asked Questions

What are the key highlights from NuCana's Q2 2026 report?

NuCana's Q2 2026 report highlights include NUC-7738 data on track for 2026 and a cash runway extending into 2029.

What is the status of the NUC-7738 Phase 2 study?

The final data from the Phase 2 expansion study of NUC-7738 is on track for release in 2026.

What future plans does NuCana have for NUC-7738?

NuCana plans to advance additional indications and combination strategies for NUC-7738.

ShareAdd on Google
Tags: NCNA Viatris Investor Conferences Healthcare NuCana NUC-7738 Phase 2 study financial results
Last updated: Aug 13, 2026

Biotech snapshot

Lead asset
NUC-3373 + leucovorinPhase 1
Colorectal Cancer →

Catalyst track record

+151%
best trade around NCNA's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for NCNA.

See every catalyst's timing & PoA →